PPARG and type 2 diabetes mellitus: Since the treatment of T2DM with full PPARγ agonists including TZD drugs is associated with many severe side effects, the development of new classes of alternative PPARγ ligands with partial agonism has received intensive research focus in modern medicinal chemistry.